Study of patritumab deruxtecan for children with hard-to-treat solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have rhabdomyosarcoma or hepatoblastoma that has spread or cannot be removed by surgery.
- Your cancer must have gotten worse after at least one prior treatment, and no other standard treatments are available for you.
- Any side effects from previous treatments must have mostly gone away (except for hair loss or nerve problems that are mild, or hormone issues managed with medication).
- If you have hepatitis B, you must be on antiviral therapy and have no detectable virus. If you have hepatitis C, the virus must be undetectable.
- You cannot have had a solid organ or stem cell transplant, certain lung problems, active brain tumors, or serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ifinatamab deruxtecan in children whose solid tumors (cancers that form lumps, excluding brain tumors) have come back or stopped responding to previous treatments. The drug is designed to target and kill cancer cells while potentially causing fewer side effects than standard chemotherapy.
This trial tests a new drug (patritumab deruxtecan) for people with advanced or spreading cancers of the digestive system (including colorectal, bile duct, liver, and stomach/esophageal cancers). The goal is to see if it can shrink tumors or stop them from growing.
This trial tests a combination of targeted therapies (patritumab deruxtecan plus pembrolizumab) along with other anticancer drugs for people with a high-risk type of early-stage breast cancer that is either triple-negative or has very low hormone receptors and is HER2-negative. The goal is to see if this approach can help prevent the cancer from coming back.
This trial tests a form of the drug trastuzumab deruxtecan that is given as a shot under the skin for people with certain metastatic solid tumors, including breast cancer and non-small cell lung cancer with HER2 changes. It aims to see how well the shot works and if it is safe.
This Phase 1 study tests codrituzumab, an antibody medicine, in children and young adults whose solid tumor has come back or did not respond to standard treatment. It’s designed to see how the treatment works and how safe it is, especially for tumors that test positive for GPC3.
This trial tests a new drug called patritumab deruxtecan (a targeted therapy) for people with a common type of advanced breast cancer (HR+/HER2-). It's for those whose cancer has grown despite treatment with a CDK4/6 inhibitor plus hormone therapy.
Hear when a new Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.